Improving Drug Safety – Without FDA: HHS Adverse Event Report Focuses On Other Agencies
This article was originally published in RPM Report
Executive Summary
HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.
You may also be interested in...
HHS’ Adverse Drug Event Action Plan Calls For New Treatment Guidelines
Draft recommends research and initiatives that could lead to changes in drug prescribing practices to reduce the likelihood of adverse drug events – and may even include more prescribing if adverse drug events can be mitigated.
Selling Sentinel: FDA Highlights Vision For Broader Role For Data Network At Brookings
FDA’s Janet Woodcock used her time at a conference on biomedical innovation to highlight ways to use FDA’s Sentinel network more broadly to standardize, and hopefully streamline comparative effectiveness research.
CMS and Opioids: The Role for Non-Drug Reimbursements
The Centers for Medicare and Medicaid Services proposed Part D rules to give plans some responsibility for monitoring opioid abuse. But providers at a Senate Finance Hearing think CMS reimbursements beyond drugs can have a role in screening abuse – and in treating pain to begin with.